Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABSI Absci Corporation.

Pre-Mkt 03-04 08:22:48 EST

2.57

-0.23

-8.21%

盘前2.72

+0.15+5.84%

08:14 EST

High2.73	Low2.56	Vol2.87M
Open2.63	D1 Closing2.80	Amplitude6.07%
Mkt Cap386.45M	Tradable Cap326.39M	Total Shares150.37M
T/O7.58M	T/O Rate2.26%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABSI","market":"US","secType":"STK","nameCN":"Absci Corporation.","latestPrice":2.57,"timestamp":1772571600000,"preClose":2.8,"halted":0,"volume":2868374,"hourTrading":{"tag":"盘前","latestPrice":2.72,"preClose":2.57,"latestTime":"08:14 EST","volume":71636,"amount":192970.1698692,"timestamp":1772630047555,"change":0.15,"changeRate":0.058366,"amplitude":0.031128},"delay":0,"changeRate":-0.08214285714285714,"floatShares":127000000,"shares":150371531,"eps":-0.896554,"marketStatus":"Pre-Mkt","change":-0.23,"latestTime":"03-04 08:22:48 EST","open":2.625,"high":2.73,"low":2.56,"amount":7576185.4759802,"amplitude":0.060714,"askPrice":2.73,"askSize":100,"bidPrice":2.62,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.896554,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772634600000},"marketStatusCode":1,"adr":0,"listingDate":1626926400000,"exchange":"NASDAQ","adjPreClose":2.57,"preHourTrading":{"tag":"盘前","latestPrice":2.72,"preClose":2.57,"latestTime":"08:14 EST","volume":71636,"amount":192970.1698692,"timestamp":1772630047555,"change":0.15,"changeRate":0.058366,"amplitude":0.031128},"postHourTrading":{"tag":"盘后","latestPrice":2.67,"preClose":2.57,"latestTime":"19:37 EST","volume":219209,"amount":576398.2901,"timestamp":1772584663402,"change":0.1,"changeRate":0.038911,"amplitude":0.046693},"volumeRatio":1.400864769745502,"impliedVol":1.0952,"impliedVolPercentile":0.48},"requestUrl":"/m/hq/s/ABSI/wiki","defaultTab":"wiki","newsList":[{"id":"2616773673","title":"Absci Director Menelas N Pangalos Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616773673","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616773673?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:09","pubTimestamp":1772575740,"startTime":"0","endTime":"0","summary":"Menelas N Pangalos, a director, reported an acquisition of common shares of Absci Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL2NnqBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Absci Director Menelas N Pangalos Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4139","BK4121","BK4539"],"gpt_icon":0},{"id":"2616328898","title":"BRIEF-Absci Strengthens Clinical Leadership With Appointment Of Ransi Somaratne, M.D., FACC, Mba As Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616328898","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616328898?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:04","pubTimestamp":1772543090,"startTime":"0","endTime":"0","summary":"BRIEF-Absci Strengthens Clinical Leadership With Appointment Of Ransi Somaratne, M.D., FACC, Mba As Chief Medical OfficerMarch 3 (Reuters) - Absci Corp ABSI.O:ABSCI STRENGTHENS CLINICAL LEADERSHIP WIT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA31QFGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ABSI","BK4121"],"gpt_icon":0},{"id":"2616404343","title":"Absci Strengthens Clinical Leadership With Appointment of Ransi Somaratne, M.d., Facc, MBA as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616404343","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616404343?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA31QFGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABSI","BK4539","BK4139"],"gpt_icon":0},{"id":"2616340760","title":"Press Release: Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340760","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340760?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542800,"startTime":"0","endTime":"0","summary":"Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline. Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash. and NEW YORK, March 03, 2026  -- Absci Corporation , a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics.Dr. Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen.Alongside Dr. Somaratne's appointment, Absci announced the ret","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","TM","03160","BK4604","BK4099","BK4539","R","BK4121","BK4022","BK4023","BK4528","BK4587","BK4232","AIYY","BK4196","BK4543","MD","BK4555","BK4585","ABSI","BK4588"],"gpt_icon":1},{"id":"2613711400","title":"Absci Corporation Updates Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613711400?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:02","pubTimestamp":1771938163,"startTime":"0","endTime":"0","summary":"Absci Corporation Updates Financial Calendar               Absci Corporation will report business updates and its fourth quarter and full year 2025 financial and operating results after market close o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL2yXjKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","BK4121","BK4112","LU0314104364.USD","SG9999014005.SGD","SG9999014039.USD","ABSI","NDAQ","BK4539","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":0},{"id":"2610666389","title":"11 Stocks That Have Cratered and Look Like Buys -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610666389?lang=en_us&edition=fundamental","pubTime":"2026-02-10 03:22","pubTimestamp":1770664920,"startTime":"0","endTime":"0","summary":"Sometimes, an opportunity to buy something is hiding in plain sight. That is a distinct possibility today, considering the tons of stocks that have crashed recently.Enormous drops in stocks have historically provided some of the best buying opportunities. When a concern emerges, prices fall to levels that fully reflect the worry, whether the risk that caused the selloff materializes or not. That sets the shares up to benefit from any improvement in sentiment.Elsewhere, companies that provide private loans and equity financing, via private investment funds, have seen their stocks tank. Even shares of the investment bank Jefferies, which owns a stake in a hedge fund that had exposure to private credit, are down 14% from a multimonth high hit in September. To make the list, short interest had to be in the 65th percentile of the historic range for each company, or higher, meaning that the st","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ9MQY76.HKD","LU2125909916.SGD","LU1670627923.USD","BK4535","LU2210150020.SGD","LU0203345920.USD","LU1261432733.SGD","LU1670628061.USD","LU0795875086.SGD","LU0795875169.SGD","LU1035773651.USD","CRM","LU0496365809.HKD","LU0942090050.USD","LU1917777945.USD","IE00B19Z8X17.USD","LU2458330243.SGD","LU0823416689.USD","LU0345770308.USD","LU1064131342.USD","SGXZ81514606.USD","LU2458330169.SGD","SG9999001424.SGD","IE00BJTD4N35.SGD","LU0198837287.USD","IE00B19Z3B42.SGD","LU0820561909.HKD","IE00BQXX3C00.GBP","LU0251131958.USD","BK4585","LU0823434583.USD","LU2063271972.USD","LU0861579265.USD","LU2089984988.USD","LU1023059063.AUD","LU0511384066.AUD","LU1815333072.USD","LU0345774631.USD","IE0009355771.USD","LU1066051498.USD","LU0949170772.SGD","LU0320765059.SGD","LU2023251221.USD","IE00B1BXHZ80.USD","LU1069347547.HKD","BK4581","LU2361045086.USD","LU0058720904.USD","LU0965509101.SGD","LU1267930813.SGD","LU2286300806.USD","BK4533","LU2242649171.HKD","LU2247934214.USD","LU1046421795.USD","LU0057025933.USD","LU1633808545.USD","UNHG","BK4608","LU0053666078.USD","IE00BJT1NW94.SGD","LU2210149790.SGD","LU2468319806.SGD","IE00B894F039.SGD","LU0170899867.USD","SG9999001176.USD","LU0265550946.USD","LU0079474960.USD","LU0787776722.HKD","SG9999018865.SGD","LU0661504455.SGD","LU0965509010.AUD","LU1551013342.USD","LU1934455863.HKD","LU1674673691.USD","RXRX","LU0342679015.USD","LU0889566641.SGD","LU2357305700.SGD","LU0882574055.USD","LU1791710400.SGD","BK4097","LU1718418525.SGD","LU0251132253.USD","SG9999002232.USD","IE00BYQQ9H92.USD","BK4554","LU0708995401.HKD","LU2552382058.USD","IE0004445239.USD","IE00BMPRXR70.SGD","LU1974910355.USD","LU1496350171.SGD","LU2362541513.USD","LU1951198990.SGD","LU2361044865.SGD","BK4154","SDGR","ADBE","IE00BWXC8680.SGD","LU2491050071.SGD","LU1267930227.SGD","LU2362540622.SGD","IE00B19Z3581.USD","IE00BJJMRY28.SGD","LU1989772923.USD","IE00BJJMRX11.SGD","LU2023250843.SGD","LU2087625088.SGD","LU1037948541.HKD","LU2279689827.SGD","LU0648001328.SGD","LU1778281490.HKD","LU1066051811.HKD","LU2125154778.USD","LU0267386448.USD","IE00BJTD4V19.USD","LU1854103824.USD","SGXZ99366536.SGD","IE00BFSS7M15.SGD","LU0672654240.SGD","LU2095319765.USD","LU0052756011.USD","LU0011850046.USD","LU1814569148.SGD","SG9999000418.SGD","LU1989764748.USD","LU0708994859.HKD","LU0289739343.SGD","LU2264538146.SGD","LU0683600562.USD","BK4588","LU1934455277.USD","LU0456855351.SGD","LU2324357040.USD","LU0792757196.USD","IE00B4R5TH58.HKD","LU2023250504.SGD","ABSI","LU0082616367.USD","LU1732799900.SGD","LU0211326839.USD","LU1720051017.SGD","LU0345774391.USD","BK4023","LU0289739699.SGD","IE00BKPKM429.USD","LU0912757837.SGD","LU2271345857.HKD","LU2543165471.USD","LU0943347566.SGD","LU0980610538.SGD","IE00B2B36J28.USD","LU0251142724.SGD","SGXZ51526630.SGD","LU0256863811.USD","LU2106854487.HKD","LU0689626769.HKD","LU0187121727.USD","LU2552382132.HKD","LU0354030438.USD","BK4607","UNH","LU0114720955.EUR","LU1934455194.USD","LU1116320901.HKD","LU1674673428.USD","LU2756315664.SGD","BK4534","LU0128525929.USD","SG9999014906.USD","LU0868494708.USD","LU0203347892.USD","LU0061474960.USD","LU1989764664.SGD","LU1003077747.HKD","LU1823568750.SGD","LU0265550359.USD","LU0234572021.USD","BK4548","LU1037948897.HKD","LU2236285917.USD","LU0545039389.USD","IE00B7SZLL34.SGD","LU0719512351.SGD","LU1316542783.SGD","LU0158827781.USD","LU1720051108.HKD","LU1804176565.USD","LU0353189763.USD","LU0077335932.USD","LU0081259029.USD","LU0048584097.USD","LU0097036916.USD","SG9999017495.SGD","IE00B7KXQ091.USD","LU0122379950.USD","UNHW","LU0211328371.USD","LU0557290698.USD","LU0048573561.USD","IE0004445015.USD","IE00BN29S564.USD","LU2125909759.SGD","LU0965508806.USD","LU0976567544.SGD","LU1623119135.USD","LU0127658192.USD","LU0238689110.USD","LU1291159041.SGD","BK4528","LU2362541273.HKD","LU0157215616.USD","LU0109391861.USD","LU1951200564.SGD","BK4532","LU2491049909.HKD","LU0957791311.USD","LU1057294990.SGD","LU2089283258.USD","IE00BZ1G4Q59.USD","LU0310800965.SGD","LU1235294995.USD","BK4561","IE00B1XK9C88.USD","BK4579","IE00B4JS1V06.HKD","SG9999002224.SGD","LU0006306889.USD","LU1914381329.SGD","BK4566","LU1989771016.USD","LU1923623000.USD","LU2433249047.HKD","IE00BKVL7J92.USD","LU2756315318.SGD","LU2461242641.AUD","IE00B19Z9Z06.USD","LU1066051225.USD","ABCL","IE00B19Z9P08.USD","LU1854104046.USD","LU0106261372.USD","IE0002141913.USD","LU2112291526.USD","LU2347655156.SGD","LU0472753341.HKD","SG9999014880.SGD","LU1119994496.HKD","LU2125909247.SGD","LU0553294199.USD","LU0128525689.USD","LU2125909593.SGD","LU0689472784.USD","LU0889565833.HKD","LU0314104364.USD","LU0528227936.USD","LU0868494617.USD","LU2111349929.HKD","LU0211327993.USD","IE00BFSS8Q28.SGD","LU0094547139.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","IE00B5TLWC47.USD","IE0005OL40V9.USD","IE00BSNM7G36.USD","BK4503","LU2133065610.SGD","LU1551013425.SGD","LU0965509283.SGD","BK4538","LU0130102774.USD","LU0316494557.USD","LU0477156953.USD","LU0738911758.USD","LU2244417387.USD","LU2361044949.HKD","LU1366333091.USD","LU2317271919.USD","BK4592","LU1084165304.USD","LU1201861249.SGD","LU2265009873.SGD","SGXZ57979304.SGD","NOW","LU2125154935.USD","LU1267930490.SGD","LU1066053197.SGD","LU2360032135.SGD","LU1923622614.USD","LU1267930730.SGD","LU0158827948.USD","IE0002270589.USD","LU1712237335.SGD","LU0289961442.SGD","LU1988902786.USD","LU1323610961.USD","LU1691799644.USD","SG9999014898.SGD","LU0124676726.USD","LU2237438978.USD","BK4505","LU0348723411.USD","LU0417517546.SGD","LU0820561818.USD","LU0823434740.USD","LU2089284900.SGD","BK4567","IE000M9KFDE8.USD","LU0310800379.SGD","SG9999001176.SGD","LU1153585028.USD","LU1116320737.USD","LU1989772840.SGD","LU2381873111.SGD","LU0109392836.USD","LU1923622291.USD","IE00BMPRXN33.USD","LU0354030511.USD","IE00B775H168.HKD","LU0742534661.SGD","LU1074936037.SGD","LU0069063385.USD","LU2028103732.USD","LU0353189680.USD","LU2211815571.USD","BK4543","BK4598","LU1803068979.SGD","IE00BQXX3D17.EUR","LU0266013472.USD","IE0009356076.USD","LU0211326755.USD","LU1061106388.HKD","BK4613","IE00BFXG0V08.USD","LU1267930573.SGD","BK4550","IE00BQXX3F31.USD","IE00BFXG1179.USD","LU0820562030.AUD","LU1791710582.SGD","LU1732800096.USD","IE00B19Z9505.USD","LU0107464264.USD","OWL","LU0310799852.SGD","LU1506573853.SGD","LU2491050154.USD","SAIL","LU0345770993.USD","SG9999018857.SGD","LU0149725797.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU2552382215.SGD","LU0642271901.SGD","SGXZ31699556.SGD","WDAY","LU0029864427.USD","LU0234570918.USD","SG9999014914.USD","LU1983299246.USD","LU1496350502.SGD","LU1548497426.USD","LU0130517989.USD","IE00B19Z8W00.USD","BK4527"],"gpt_icon":0},{"id":"2609591192","title":"Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble","url":"https://stock-news.laohu8.com/highlight/detail?id=2609591192","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609591192?lang=en_us&edition=fundamental","pubTime":"2026-02-06 18:40","pubTimestamp":1770374408,"startTime":"0","endTime":"0","summary":"Insiders who bought US$582.6k worth of Absci Corporation's ( NASDAQ:ABSI ) stock at an average buy price of US$2.98...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-absi/absci/news/insiders-who-purchased-us5826k-of-absci-stock-may-not-have-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-absi/absci/news/insiders-who-purchased-us5826k-of-absci-stock-may-not-have-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","BK4539","BK4139","ABSI"],"gpt_icon":0},{"id":"2606203784","title":"The Genesis Mission Has a 270-Day Timeline – And You’re Already Late","url":"https://stock-news.laohu8.com/highlight/detail?id=2606203784","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606203784?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:56","pubTimestamp":1769518560,"startTime":"0","endTime":"0","summary":"The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/hypergrowthinvesting/2026/01/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/hypergrowthinvesting/2026/01/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["NVDD","CEG","LEU","3NVD.UK","NVD3.UK","SLI","NVD2.UK","NVDS","TMO","NVDU","SDGR","PPTA","SYM","OKLO","NVDG","NVII","NVDY","TWST","MUD","DNA","WOLF","NVD","SKYT","AI","ROK","RXRX","TMQ","IONQ","INTC","SNVD.UK","NVDW","NVDQ","2NVD.UK","HON","TER","NVDX","ABSI","DIPS","NNE","MULL","BWXT"],"gpt_icon":1},{"id":"2603623062","title":"Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603623062","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603623062?lang=en_us&edition=fundamental","pubTime":"2026-01-15 08:22","pubTimestamp":1768436557,"startTime":"0","endTime":"0","summary":"Absci Corporation presented new developments at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress in generative AI-driven drug discovery. The company showcased its industrialized platform that combines AI and wet-lab capabilities to accelerate and reduce the cost of drug discovery, moving from initial code to clinical-stage programs in as little as 24 months. The presentation detailed three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease . ABS-201, targeting PRLR inhibition, was noted as a potential new category of therapy for hair regrowth, aiming to address significant unmet needs in androgenetic alopecia with an innovative approach distinct from current treatments. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL2mtfp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ABSI","BK4121","BK4139"],"gpt_icon":0},{"id":"2601630273","title":"Absci downgraded to Equal Weight from Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2601630273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601630273?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:15","pubTimestamp":1767870921,"startTime":"0","endTime":"0","summary":"Morgan Stanley downgraded Absci (ABSI) to Equal Weight from Overweight with a price target of $4.32, down from $5.80. The latest company and pipeli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/absci-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/absci-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1548497426.USD","LU1668664300.SGD","LU0795875169.SGD","ABSI","BK4516","BK4534","IE00BKVL7J92.USD","LU0528227936.USD","LU0795875086.SGD","LU1989772840.SGD","LU0971096721.USD","LU0314104364.USD","LU2347655156.SGD","BK4139","LU0158827781.USD","LU0098860793.USD","LU0882574139.USD","LU2028103732.USD","LU1791710582.SGD","LU1074936037.SGD","LU1162221912.USD","LU2089283258.USD","LU0006306889.USD","LU0234570918.USD","LU0267386448.USD","LU2357305700.SGD","BK4121","LU0557290698.USD","LU1363072403.SGD","LU2133065610.SGD","BK4585","BK4539","BK4504","LU1720051017.SGD","BK4127","LU2089284900.SGD","LU1732799900.SGD","LU0158827948.USD","BK4581","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU1244550221.USD","LU1244550494.USD","LU1989772923.USD","LU2111349929.HKD","LU0912757837.SGD","LU1732800096.USD","LU1720051108.HKD","LU1244550577.SGD","LU0225283273.USD"],"gpt_icon":0},{"id":"2590503068","title":"Absci Price Target Maintained With a $7.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503068?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:50","pubTimestamp":1765540200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABSI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 06:50 ET (11:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABSI","BK4539","BK4121"],"gpt_icon":0},{"id":"2590015515","title":"Absci Unveils AI-Designed Antibody That Stimulates Human Hair Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2590015515","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590015515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458019,"startTime":"0","endTime":"0","summary":"Absci Corporation has unveiled new preclinical data demonstrating that its AI-designed antibody, ABS-201, effectively stimulates hair growth in human ex vivo scalp models. The research shows that ABS-201 targets the prolactin receptor and promotes hair follicle regeneration by restoring the stem cell niche and influencing key growth modulators. The data suggest ABS-201 may reverse follicular miniaturization and drive the transformation from vellus to terminal hair, offering a potential new approach for treating androgenetic alopecia. These findings were presented during Absci's ABS-201 Key Opinion Leader seminar, with the full dataset and detailed results made available in a slide presentation on the company's investor relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbJvgGy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4139","BK4121","LU2210150020.SGD","NDAQ","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD","BK4539","BK4112","ABSI","BK4585","BK4588","SG9999014021.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590516989","title":"Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516989","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516989?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growthex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular mini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203834/0/en/Absci-Reports-New-Human-Ex-Vivo-Data-Demonstrating-That-ABS-201-Stimulates-Hair-Growth-and-Regenerates-Stem-Cell-Niche-to-Potentially-Reverse-Follicle-Miniaturization.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4121","KOL","BK4539","BK4139"],"gpt_icon":0},{"id":"2590632126","title":"Absci Director Frans Van Houten Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590632126","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590632126?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:04","pubTimestamp":1765314290,"startTime":"0","endTime":"0","summary":"Frans Van Houten, a Director at Absci Corporation, has reported the acquisition of common shares of Absci Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL61xFn3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Absci Director Frans Van Houten Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ABSI","BK4139","BK4121"],"gpt_icon":0},{"id":"2588388260","title":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588388260","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588388260?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:24","pubTimestamp":1764854658,"startTime":"0","endTime":"0","summary":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial Dec 4  - Absci Corp ABSI.O:ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE TRIAL OF AI-DESIGNED ANTIBODY ABS-201 FOR ANDROGENETIC ALOPECIAABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026Source text: ID:nGNXR58yFurther company coverage: ABSI.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4139","BK4121","BK4539"],"gpt_icon":0},{"id":"2588884143","title":"Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884143","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884143?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853216,"startTime":"0","endTime":"0","summary":"Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor  antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL367TTr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ABSI","IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","BK4139","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4588","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD","BK4121"],"gpt_icon":0},{"id":"2588884901","title":"Absci Announces First Participants Dosed in Phase 1/2a Headline™ Trial of AI-Designed Antibody Abs-201™ for Androgenetic Alopecia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884901?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABSI","BK4539","BK4139"],"gpt_icon":0},{"id":"2588844708","title":"Absci Corp: Interim Data Anticipated in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588844708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588844708?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4121","BK4539","ABSI"],"gpt_icon":0},{"id":"2588188440","title":"Absci Corp - Phase 2 Development of Abs-201 in Endometriosis Planned for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188440?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4121","BK4539","ABSI"],"gpt_icon":0},{"id":"2588056701","title":"Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056701","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056701?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683700,"startTime":"0","endTime":"0","summary":"The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["OKLO","LU1429558221.USD","LAC","NVD","ROIC","SDGR","SGXZ31699556.SGD","WOLF","MU","LU0274383776.USD","DNA","ROK","TER","SKYT","SMR","SYM","SLI","LU2023251221.USD","AI","INTC","QBTS","NVDS","NVDU","CEG","NVIW.SI","TMQ","LU0265550359.USD","3NVD.UK","NVDD","IONQ","ABSI","NVDA","2NVD.UK","NVDS.UK","RXRX","BWXT","MP","RGTI","LEU","NVD3.UK","HON","NVDX","NVD2.UK","NVDY","TWST","SNVD.UK","TMO","NVDL","NNE","PPTA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.absci.com","stockEarnings":[{"period":"1week","weight":-0.0517},{"period":"1month","weight":-0.1405},{"period":"3month","weight":-0.2188},{"period":"6month","weight":0.0708},{"period":"1year","weight":-0.2485},{"period":"ytd","weight":-0.2636}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106318},{"month":2,"riseRate":0.6,"avgChangeRate":0.064917},{"month":3,"riseRate":0.2,"avgChangeRate":-0.116834},{"month":4,"riseRate":0.25,"avgChangeRate":-0.121758},{"month":5,"riseRate":0.25,"avgChangeRate":-0.047908},{"month":6,"riseRate":0,"avgChangeRate":-0.147252},{"month":7,"riseRate":0.75,"avgChangeRate":0.242017},{"month":8,"riseRate":0.2,"avgChangeRate":-0.131623},{"month":9,"riseRate":0.2,"avgChangeRate":-0.114873},{"month":10,"riseRate":0.8,"avgChangeRate":0.133791},{"month":11,"riseRate":0.2,"avgChangeRate":-0.134033},{"month":12,"riseRate":0.4,"avgChangeRate":0.218437}],"exchange":"NASDAQ","name":"Absci Corporation.","nameEN":"Absci Corporation."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Absci Corporation.,ABSI,Absci Corporation.股票,Absci Corporation.股票老虎,Absci Corporation.股票老虎国际,Absci Corporation.行情,Absci Corporation.股票行情,Absci Corporation.股价,Absci Corporation.股市,Absci Corporation.股票价格,Absci Corporation.股票交易,Absci Corporation.股票购买,Absci Corporation.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}